9 AC COLLOIDAL DISPERSION INFUSION IN ADVANCED NON SMALL CELL LUNG CA

9 高级非小细胞肺 CA 中的 AC 胶体分散输注

• 批准号: 6305353
• 负责人: NATHAN LEVITAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305353
• 关键词: DNA topoisomerases; antineoplastics; clinical research; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; neoplasm /cancer chemotherapy; pharmacokinetics; small cell lung cancer

The objectives of this trial are to: To determine if 9-aminocamptothecin CD administered as a 120h weekly infusion is an effective agent of treatment of advanced non-small cell lung cancer. To observe the toxicity associated with this regimen among patients with advanced nonsmall cell lung cancer. To measure the levels of topoisomerase I in tumor biopsy specimens obtained from patients with non small cell lung cancer entered on this trial. To determine the 9-AC pharmacokinetics parameters and to correlate serum levels with toxicity and response to treatment. To determine the mutagenic potential of 9-AC administered as a 120hr weekly infusion."

本试验的目的是：确定每周输注120小时的9-氨基amptothecin CD是否是治疗晚期非小细胞肺癌的有效药物。观察该方案对晚期非小细胞肺癌患者的毒性。本试验旨在测量非小细胞肺癌患者肿瘤活检标本中拓扑异构酶I的水平。确定9-AC的药代动力学参数，并将血清水平与毒性和治疗反应联系起来。确定每周输注120小时的9-AC的致突变潜力。